지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.4
- 수록면
- 542 - 550 (9page)
- DOI
- 10.4143/crt.2022.834
이용수
초록· 키워드
오류제보하기
Purpose This study investigated pathological complete response (pCR) according to androgen receptor (AR) in breast cancer patients undergoing neoadjuvant chemotherapy and estimated the relationship between AR expression and clinicopathological factors.
Materials and Methods We identified 624 breast cancer patients who underwent surgery after neoadjuvant chemotherapy at the National Cancer Center in Goyang, Korea from April 2016 to October 2019. We retrospectively collected the clinicopathologic information and AR expression results and analyzed the data according to cancer stage, hormonal receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, tumor subtype, and pCR.
Results Among the 624 breast cancer patients, 529 (84.8%) were AR-positive (AR+) patients and 95 (15.2%) were AR-negative (AR–) patients. AR+ patients showed more estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, HER2-positivity, and HR-positive and HER2-negative (HR+/HER2–) subtype. The rate of pCR was 31.4% (196/624). AR– patients had a significantly higher rate of pCR than AR+ patients (AR– 43.2% vs. AR+ 29.3%, p=0.007). The tumor factors associated with pCR were early stage, histologic grade 3, ER-negative, PR-negative, AR-negative, HER2-positive, and high Ki-67 values. In univariable analysis, AR+ significantly decreased the state of pCR (odds ratio, 0.546; 95% confidence interval, 0.349 to 0.853; p=0.008). According to tumor subtype, AR– tumor showed higher pCR rate in HR+/HER2– subtype (AR– 28.6% vs. AR+ 7.3%, p=0.022).
Conclusion AR expression is predominant in the HR+/HER2– subtype. AR– is significantly associated with the pCR rate in breast cancer patients, especially within HR+/HER2– subtype. When determining neoadjuvant chemotherapy for the HR+/HER2– subtype, AR expression can be considered as a pCR predictive marker.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Predictive Factor of the Pathologic Complete Response after the Neoadjuvant Treatment of the HER2 Positive Breast Cancer
대한외과학회 학술대회 초록집
2022 .05
-
Mean Platelet Volume as an Independent Predictive Marker for Pathologic Complete Response after Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Predictive Factors for Pathologic Complete Response after Preoperative Chemotherapy in Triple-Negative Breast Cancer
대한임상종양학회 학술대회지
2016 .02
-
Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
대한외과학회 학술대회 초록집
2017 .11
-
Prediction of Axillary Lymph Node Response Based on Breast Pathologic Complete Response and Breast Cancer Subtype after Neoadjuvant Chemotherapy
대한임상종양학회 학술대회지
2019 .02
-
MicroRNA-222 Expression as a Predictive Marker for Tumor Progression in Hormone Receptor-Positive Breast Cancer
Journal of Breast Cancer
2017 .01
-
Radiologic complete response after neoadjuvant chemotherapy in advanced breast cancer can predict survival outcome, but not pathologic complete response
대한외과학회 학술대회 초록집
2019 .10
-
[Breast] Risk Factors of Breast Cancer Recurrence in Pathologic Complete Response (pCR) Achieved Post Neoadjuvant Chemotherapy (NAC) Patients
대한외과학회 학술대회 초록집
2022 .11
-
[Breast] MRI in the Prediction of Pathological Complete Response in Breast Cancer Patients after Neoadjuvant Chemotherapy
대한외과학회 학술대회 초록집
2022 .11
-
The Optimal Treatment Strategy in Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer Patients with 1-2 Suspicious Axillary Lymph Node on Breast MRI: Upfront Surgery vs.Neoadjuvant Chemotherapy?
대한외과학회 학술대회 초록집
2022 .05
-
Omission of Chemotherapy for Hormone Receptor Positive and Her2-negative Breast Cancer: Patterns of Treatment and Outcomes from The Korean Breast Cancer Registry
대한외과학회 학술대회 초록집
2020 .11
-
Oncology Efficacy of Gonadotropin-Releasing Hormone Agonist in Hormone Receptor-Positive Very Young Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
대한외과학회 학술대회 초록집
2018 .11
-
Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin
Journal of Breast Cancer
2019 .01
-
A comparative study of the clinical characteristics and outcomes of hormone receptor positive, HER2 negative breast cancer patients over 65 years old and under 65 years old patients
대한임상종양학회 학술대회지
2020 .07
-
Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
Journal of Breast Cancer
2019 .01
-
Effects of ginseng on two main sex steroid hormone receptors : estrogen and androgen receptors
Journal of Ginseng Research
2017 .04
-
[Breast] Analysis on Predictive Markers of Breast Cancer Refractory to Neoadjuvant Docetaxel Chemotherapy Following Adriamycin and Cyclophosphamide
대한외과학회 학술대회 초록집
2021 .11
-
Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome
Cancer Research and Treatment
2016 .01
-
The Role of Neoadjuvant Chemotherapy in Patients with ER Positive and HER2 Negative Breast Cancer
대한외과학회 학술대회 초록집
2018 .11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0